Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.63M | -13.72M | -30.63M | -20.77M | -13.15M |
| Total Depreciation and Amortization | 17.00K | 16.00K | 59.00K | 134.00K | 135.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.00M | -718.00K | 15.35M | 5.63M | 2.36M |
| Change in Net Operating Assets | -1.08M | 176.00K | -1.15M | 3.61M | 1.20M |
| Cash from Operations | -17.69M | -14.25M | -16.37M | -11.39M | -9.46M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.51M | 2.40M | -13.26M | -70.86M | -- |
| Cash from Investing | 25.51M | 2.40M | -13.26M | -70.86M | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.18M | 1.15M | 14.37M | 40.00K | -- |
| Repurchase of Common Stock | -779.00K | 0.00 | -1.00K | -509.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -462.00K | -- | -- | -- |
| Cash from Financing | 1.40M | 687.00K | 14.37M | -469.00K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.21M | -11.16M | -15.26M | -82.72M | -9.46M |